Guanfacine Tablet, Extended Release
Product Images NDC 71335-2379

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 71335-2379). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure2 (Guanfacine 2figure)

A chart depicting the pharmacokinetic fold change and 90% confidence intervals for various substances affecting GUANFACINE absorption or metabolism. It lists CYP3A4/5 inhibitors (Ketoconazole, Fluconazole), CYP3A4 inducers (Rifampin, Efavirenz), and other drugs (Oral Methylphenidate, Lisdexamfetamine Dimesylate), showing changes in Cmax and AUC relative to reference values on a horizontal axis ranging from 0 to 5.*

FDA Label Image

Figure 3 (Guanfacine 3 Figure)

A chart showing pharmacokinetic fold changes and 90% confidence intervals for interacting drugs Oral Methylphenidate and Lisdexamfetamine Dimesylate. The metrics Cmax and AUC are plotted relative to a reference value of 1, indicating no significant change in exposure when coadministered with guanfacine.*

FDA Label Image

Figure1 (Guanfacine Figure 1)

A pharmacokinetic plasma concentration-time curve comparing extended-release and immediate-release Guanfacine at 1 mg once daily dosing. The Y-axis shows Guanfacine plasma concentration (ng/mL) and the X-axis shows time in hours (up to 24 hours). The extended-release form displays a gradual rise and sustained concentration, while the immediate-release peaks sharply then declines.*

FDA Label Image

Figure 4 (Guanfacine Figure4)

A line graph illustrating treatment failure over time (days) comparing placebo and SPD503. The y-axis represents treatment failure percentage, and the x-axis tracks time in days. The graph shows two curves: a solid line for placebo and a dashed line for SPD503, demonstrating different rates of treatment failure over the observation period.*

FDA Label Image

Structure (Guanfacine Str)

Chemical structure diagram of guanfacine hydrochloride showing its molecular components including chlorine atoms, amine groups, and hydrochloride salt.*

FDA Label Image

Label (Lbl713352379)

Label for Guanfacine Extended-Release Tablets, 1 mg, oral dosage form. The package contains 30 tablets. The product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Alembic Pharmaceuticals Limited. The label includes NDC 71335-2379-1 and storage instructions at 20° to 25°C (68° to 77°F). It advises not to crush, chew or break tablets before swallowing and to keep medications out of children's reach.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.